Population-level effects of human papillomavirus vaccination programs on infections with nonvaccine genotypes

David Mesher, Kate Soldan, Matti Lehtinen, Kimberley Kavanagh, Simon Beddows, Marc Brisson, Julia M.L. Brotherton, Eric P.F. Chow, Teresa Cummings, Mélanie Drolet, Christopher K. Fairley, Suzanne M. Garland, Jessica A. Kahn, Kimberley Kavanagh, Lauri Markowitz, Kevin G. Pollock, Anna Söderlund-Strand, Pam Sonnenberg, Sepehr N. Tabrizi, Clare TantonElizabeth Unger, Sara L. Thomas

Research output: Contribution to journalArticlepeer-review

52 Citations (Scopus)
80 Downloads (Pure)

Abstract

We analyzed human papillomavirus (HPV) prevalences during prevaccination and postvaccination periods to consider possible changes in nonvaccine HPV genotypes after introduction of vaccines that confer protection against 2 high-risk types, HPV16 and HPV18. Our meta-analysis included 9 studies with data for 13,886 girls and women ≤19 years of age and 23,340 women 20–24 years of age. We found evidence of cross-protection for HPV31 among the younger age group after vaccine introduction but little evidence for reductions of HPV33 and HPV45. For the group this same age group, we also found slight increases in 2 nonvaccine high-risk HPV types (HPV39 and HPV52) and in 2 possible high-risk types (HPV53 and HPV73). However, results between age groups and vaccines used were inconsistent, and the increases had possible alternative explanations; consequently, these data provided no clear evidence for type replacement. Continued monitoring of these HPV genotypes is important.
Original languageEnglish
Pages (from-to)1732-1740
Number of pages9
JournalEmerging Infectious Diseases
Volume22
Issue number10
DOIs
Publication statusAccepted/In press - 29 Jun 2016

Keywords

  • HPV
  • human papillomavirus
  • vaccination programmes

Cite this